JAK3 inhibitors have become a buzzword in pharmaceuticals, with significant implications for treating various diseases, including autoimmune disorders and cancers. JAK (Janus Kinase) inhibitors, ...
Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who cycled JAK inhibitors after inadequate response had a 38.7% remission ...
NB: this presentation will be the subject of an embargoed news briefing by co-author Dr Kevin Kalinsky on Monday 24 October at 17.00 hrs CEST. Barcelona, Spain: In a trial matching new treatments to ...
An expert discusses the value of Jaypirca’s recent accelerated FDA approval for relapsed/refractory mantle cell lymphoma, as well as where treatment may go next. The FDA approval of Jaypirca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback